Home Products Most Popular Contact
No items in your cart.
The page below is a sample from the LabCE course Laboratory Diagnosis of Cystic Fibrosis. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Laboratory Diagnosis of Cystic Fibrosis (online CE course) »
How to Subscribe
MLS & MLT Comprehensive CE Package
Includes 123 CE courses, most popular
$95 Add to cart
Pick Your Courses
Up to 8 CE hours
$50 Add to cart
Individual course$20 Add to cart

Pulmonary Disease

The pulmonary disease in CF is chronic and progressive. It is characterized by a cycle of inflammation and infection, which destroys lung tissue and leads to scarring. Patients with CF have a persistent cough and increased sputum production. Small airways are congested with thick mucus and colonized shortly after birth with Staphylococcus aureus and Haemophilus influenzae. The Haemophilus tends to be supplanted by a mucoid strain of Pseudomonas aeruginosa as the patient ages. Declining pulmonary function is the leading cause of morbidity and mortality in CF. The clinical microbiology laboratory is involved in identifying the pulmonary pathogens and performing drug susceptbility testing.
Pulmonary exacerbations, characterized by increase in cough, sputum production, and shortness of breath, are treated with a variety of antibiotics; however, it can be very difficult to completely eradicate the bacteria. This is thought to be due to the development of antibiotic-resistant bacteria, the presence of mucus and bacterial capsulation (both of which make drug penetration more difficult), and the development of bacterial biofilms.*

*Simon, RH. Cystic Fibrosis: Antibiotic therapy for lung disease. UpToDate website. Last updated October 27, 2014. Available at: http://www.uptodate.com/contents/cystic-fibrosis-antibiotic-therapy-for-lung-disease. Accessed May 7, 2019.